Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
An Exploration of Neurocognitive Contributors to Functional Recovery Following Cognitive Behavioural Therapy and Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
EF 2022-23
Résumé
Major depressive disorder (MDD) is a leading cause of disability among young adults and is the largest growing cause of disability claims in Ontario. Functional impairment in MDD is associated with substantial economic and healthcare costs, increased vulnerability for recurrent depressive episodes, and decreased quality of life. Despite the existence of treatments that can reduce symptoms of depression, many individuals continue to experience persistent functional impairment. There is an urgent need to identify interventions that specifically target and improve functional outcomes for individuals with MDD. Neurocognitive impairment (i.e., difficulty with thinking abilities) largely contributes to functional impairment in MDD, and is therefore a critical treatment target for functional recovery. Emerging evidence suggests that intravenous (IV) ketamine may improve both neurocognition and functional outcomes in MDD. Integrating IV ketamine treatment with current gold-standard treatment for MDD (i.e., cognitive behavioural therapy) may effectively improve both neurocognition and functioning compared to CBT alone. This proposed study is part of a CIHR funded 12-week, multi-site, double-blinded randomized controlled trial integrating CBT and IV ketamine treatment. 140 adults with MDD will be included. All participants will receive 12 weeks of CBT, and will be randomly assigned to also receive six IV ketamine infusions or the placebo treatment over 30 days. Neurocognition and functioning will be measured at baseline and at the end of treatment. We will evaluate changes in neurocognition and functioning with combined CBT and intravenous ketamine compared to CBT alone, as well as the extent to which changes in neurocognition predict functional outcomes at the end of treatment. Findings from this study will provide preliminary support towards improving patient-centred care, quality of life, and return to work/role functioning for individuals with MDD.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
475697
Name
Lipsitz Orly
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
An Exploration of Neurocognitive Contributors to Functional Recovery Following Cognitive Behavioural Therapy and Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cognition; Cognitive Behavioural Therapy; Functional Recovery; Ketamine; Major Depressive Disorder; Randomized Clinical Trial; Treatment-Resistant Depression
Abstract
Major depressive disorder (MDD) is a leading cause of disability among young adults and is the largest growing cause of disability claims in Ontario. Functional impairment in MDD is associated with substantial economic and healthcare costs, increased vulnerability for recurrent depressive episodes, and decreased quality of life. Despite the existence of treatments that can reduce symptoms of depression, many individuals continue to experience persistent functional impairment. There is an urgent need to identify interventions that specifically target and improve functional outcomes for individuals with MDD. Neurocognitive impairment (i.e., difficulty with thinking abilities) largely contributes to functional impairment in MDD, and is therefore a critical treatment target for functional recovery. Emerging evidence suggests that intravenous (IV) ketamine may improve both neurocognition and functional outcomes in MDD. Integrating IV ketamine treatment with current gold-standard treatment for MDD (i.e., cognitive behavioural therapy) may effectively improve both neurocognition and functioning compared to CBT alone. This proposed study is part of a CIHR funded 12-week, multi-site, double-blinded randomized controlled trial integrating CBT and IV ketamine treatment. 140 adults with MDD will be included. All participants will receive 12 weeks of CBT, and will be randomly assigned to also receive six IV ketamine infusions or the placebo treatment over 30 days. Neurocognition and functioning will be measured at baseline and at the end of treatment. We will evaluate changes in neurocognition and functioning with combined CBT and intravenous ketamine compared to CBT alone, as well as the extent to which changes in neurocognition predict functional outcomes at the end of treatment. Findings from this study will provide preliminary support towards improving patient-centred care, quality of life, and return to work/role functioning for individuals with MDD.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lipsitz, Orly
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~